EUROPEAN COMMISSION

Brussels,16.6.2021
C(2021) 4513 final

PUBLIC VERSION

Igenomix, S.L.U.
Calle Narcís Monturiol Estarriol 11
Parcels B, Edificio Europark,
Parque Tecnológico de Paterna
46980 Paterna
Spain

Universal Clinics, S.L.
Calle Jose Silva 9B
Madrid
Spain

Subject: **Case M.10202 – EQT / INVESTINDUSTRIAL / JV**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004[1] and Article 57 of the Agreement on the European Economic Area[2]

Dear Sir or Madam,

1. On 21 May 2021, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which the undertaking Igenomix, S.L.U. ('Igenomix', Spain), solely controlled by EQT AB ('EQT', Sweden), and Universal Clinics, S.L. ('Universal Clinics', Spain), solely controlled by Investindustrial S.A. ('Investindustrial', Luxembourg), acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control over a newly created joint venture (the 'JV') by way of purchase of shares.[3]

2. The business activities of the undertakings concerned are:

   – for EQT: management of investment funds. Portfolio companies controlled by EQT include notably Igenomix, a company dedicated to the business of genetic and molecular diagnostics, as well as clinical and complementary

1 OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

2 OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').

3 Publication in the Official Journal of the European Union No C 205, 31.05.2021, p. 9.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.

analyses, specialized in the reproductive sector and in vitro fertilisation related testing,

- for Investindustrial: management of investment funds. Portfolio companies controlled by Investindustrial include notably Universal Clinics, a company active in reproduction medicine through the ownership, operation and development of health clinics in Spain, Italy, Czech Republic and Sweden,

- for the JV: development and commercialisation of a non-invasive embryo culture medical device to be used by in vitro fertilization laboratories.

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(a) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.[4]

4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General

4 OJ C 366, 14.12.2013, p. 5.